Over the last two decades, many companies have joined the field of cancer research. Seattle Genetics leads the pack. The biotech firm has some of the most exciting technologies in the field. The company is the brainchild of Clay Siegall, a genetic expert. Clay co-founded the company in 1998. Through his innovative ideas, funding, and leadership, Clay has managed to enhance the company’s profitability margins. The tripling of the company’s stock prices in the last five years is an evidence of the entity’s growth and high-quality leadership. Clay is the president and CEO of the firm.
Dr. Clay Seigall is a revered authority in matters of cancer research. Since earning his PhD in Genetics from George Washington University, the scientist has been involved in cancer research. He started his research career at Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator before being promoted to serve as the principal scientist. At the National Cancer Institute, he worked as the staff fellow and biotechnology fellow.
Seattle Genetics is involved in developing cancer therapies using antibody-drug conjugates (ADCs) technology. The company was the first to produce and commercialize a cancer drug using the technology. The drug, ADCETRIS, is available in over 60 countries worldwide. In 2011, FDA approved the drug. This information was originally mentioned on Salary.com .
Since developing drugs is expensive, Dr. Siegall has partnered with other companies to help push ADCs technology to its full potentials. These companies are developing different therapies under licenses provided by Seattle Genetics. In return, the company has earned millions of dollars from these licenses.
When he became Seattle Genetics’ CEO in 2002, the company was struggling with raising funds for its research and operation. The entrepreneur embarked on a campaign that saw the company undertake a successful IPO. Under his leadership, the company has raised over $1.2 billion in private and public funding.
In 2013, Dr. Siegall received the University of Maryland’s Alumnus of the Year for Computer, Math, and Natural Sciences. In 2012, he was awarded the Pacific Northwest Ernst & Young Entrepreneur of the Year. Clay is also a successful author. He has over 70 scientific papers, which have been published in varies journals. Moreover, the scientist holds 15 patents.